- Home
- ELLO vs XFOR Comparison
ELLO vs XFOR Comparison
Compare ELLO & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELLO | XFOR |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.2M | 324.4M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELLO | XFOR |
|---|---|---|
| Price | $25.75 | $3.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | 3.7K | ★ 879.6K |
| Earning Date | 12-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,742,227.00 | $33,979,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.31 | ★ 2925.74 |
| 52 Week Low | $13.00 | $1.35 |
| 52 Week High | $27.05 | $26.83 |
Technical Indicators
Market Signals| Indicator | ELLO | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 68.05 | 50.58 |
| Support Level | $23.64 | $3.50 |
| Resistance Level | $27.05 | $4.56 |
| Average True Range (ATR) | 1.14 | 0.30 |
| MACD | 0.35 | 0.01 |
| Stochastic Oscillator | 86.19 | 40.00 |
Price Performance
Historical ComparisonAbout ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.